|
 Shares of Eli Lilly & Co. gained 1.1% in premarket trading on Monday after the drugmaker said it started a Phase 3 trial for a treatment that aims to prevent COVID-19 infections in residents and workers in nursing homes. It is estimated that at least 8% of U.S. COVID-19 cases and more than 41% of deaths have occurred in people linked to nursing homes, according to The New York Times. Lilly is testing an experimental antibody it developed with the privately held AbCellera Biologics Inc. to see if it can prevent infections in people who live or work in a facility that has recently reported a case of the coronavirus. The antibody was identified in the blood sample of one of the first people in the U.S. to test positive for the virus. The trial, expected to enroll 2,400 people by September, will be conducted with the National Institute of Allergy and Infectious Diseases, with plans to release the late-stage data sometime in the fourth quarter. Lilly's stock has gained 14.3% so far this year. The S&P 500 is up 1.2%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
|
|
Reducing the risk of virus transmission is key — here is what experts know so far about the health hazards
|
|
 Stock futures rose Monday morning, pointing to a higher start to the first session of August as investors considered another set of corporate earnings reports and awaited a slew of data on the state of the labor market this week as parts of the country continue to grapple with a rise in coronavirus cases.
|
|
 For many casual observers and drinkers, hard seltzer seemed to come out of nowhere last summer. Sweeping across the country like a fizzy, buzz-making tidal wave, hot girl summer suddenly had an official beverage sponsor: White Claw. But for those in the industry or closely observing it, the rise of hard seltzer wasn't mere happenstance--consumers...
|
|
Apple has just confirmed the release of its most exciting new iPhones in years...
|
|
Private Label